Protalix BioTherapeutics, Inc. (NYSE: PLX) announced 2025 financial and operational results in a March 18 th, 2026, press release and Form 10-K filing. The reports were followed by a conference call, ...

PLX-200 is an orally available compound comprised of gemfibrozil, an FDA-approved lipid regulating agent. The company stated that gemfibrozil’s ability to cross the blood-brain barrier has been ...

Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE)-- Polaryx ...

Good morning, ladies and gentlemen, and welcome to Protalix BioTherapeutics Full Year 2025 Financial Results and Business Update Conference Call. As a reminder, this call is being recorded. I will now ...

The viewership for streaming keeps growing and growing — or does it? The next edition of “The Gauge,” a monthly snapshot from Nielsen that purports to examine all broadcast, cable and streaming ...

Protalix BioTherapeutics reported weaker FY25 results but issued robust FY26 revenue guidance of $78–83 million, well above consensus. PLX’s growth thesis centers on Elfabrio’s EU approval and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

PARAMUS, NJ, March 12, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric ...

We may earn revenue from the products available on this page and participate in affiliate programs. Learn more The Super Black Eagle 3 now comes in 3-inch 28-gauge, where it’s finding favor with ...

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's the ...